Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT

Published 06/12/2014, 02:22
© Reuters. A view of the Merck & Co. campus in Linden, New Jersey
MRK
-
MRCG
-
CBST
-

(Reuters) - Merck & Co Inc (N:MRK) is in talks to acquire Cubist Pharmaceuticals Inc (O:CBST) for more than $7 billion in a deal that could be announced as early as next week, the New York Times reported on Friday, citing people briefed on the matter.

Merck will likely pay roughly $100 a share for Cubist, valuing the company that makes drugs to fight superbugs, in the range of $7.5 billion, the people said. (http://nyti.ms/1IbKXcJ)

Merck could pay a 33 percent premium for Cubist, the sources told the newspaper, but it was not clear if it would pay for Cubist shares with cash, stock or a combination of the two.

Lexington, Massachusetts-based Cubist is valued at about $5.7 billion as of its Friday close of $74.36.

The antibiotic maker's shares rose about 22.7 percent to $91.25 on the Nasdaq in extended trade. Up to Friday's close, the stock had nearly doubled over the last three years. Merck's shares were flat.

Both companies were unavailable for comment outside of regular business hours.

Cubist reported a 16 percent jump in third-quarter sales in October, driven by strong sales of its antibiotic Cubicin, which generated global sales of more than $1 billion last year.

The company received U.S. regulatory approval for its antibiotic Sivextro in June. It awaits an FDA decision on another antibiotic, ceftolozane/tazobactam, on Dec. 21.

In June, Merck acquired Idenix Pharmaceuticals for $3.85 billion, to boost its hepatitis C drug portfolio.

© Reuters. A view of the Merck & Co. campus in Linden, New Jersey

(Reporting by Natalie Grover and Siddharth Cavale in Bengaluru; Editing by Lisa Shumaker)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.